September 24th 2024
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and chemotherapy for patients with non–small cell lung cancer in the first article of a 2-part series.
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Eftilagimod Alpha Combination Demonstrates Durable Responses in Frontline NSCLC
January 18th 2023Updated findings from the TACTI-002 trial of pembrolizumab and eftilagimod alpha in non–small cell lung cancer were presented during the Society for Immunotherapy of Cancer 37th Annual Meeting & Pre-Conference.
Read More
First-Line Combination Immunotherapy plus Chemotherapy in mNSCLC
January 18th 2023Edward B. Garon, MD, Professor of Medicine, and Director of the Thoracic Oncology group at the David Geffen School of Medicine at UCLA, reviews key clinical trial data and explains the rationale of using combination IO therapies in the treatment of non-small cell lung cancer (NSCLC).
Read More
FDA Approves FoundationOne Companion Diagnostic to Entrectinib in NSCLC
January 6th 2023The FDA has approved the liquid biopsy next-generation sequencing-based test FoundationOne Liquid CDx in companion with entrectinib for patients with non–small cell lung cancer with a ROS1 mutation in their tumor.
Read More
Management of Adverse Events Following Mobocertinib and Strategies for Treatment Modification
Dr Neal outlines second-line targeted treatment selection for the patient case, while Lauren Welch, MSN, NP-C, AOCNP, shares her experience with managing the adverse effects of mobocertinib in patients with EGFR exon 20-mutated mNSCLC and comments on potential strategies for treatment modification.
Watch
Dr Piotrowska and Lauren Welch offer insight into results interpretation and subsequent treatment decision-making for patients with mNSCLC who are found to harbor an EGFR exon 20 insertion mutation through biomarker testing.
Watch
TTFields Plus SOC Provides Survival Advantage for Patients With Stage IV NSCLC
January 5th 2023The primary end point of overall survival improvement has been reached in the phase 3 LUNAR study, which is evaluating Tumor Treating Fields in combination with standard therapies for the treatment of stage IV non–small cell lung cancer.
Read More
Immunotherapy, Targeted Therapy Enter Localized Setting in Non–Small Cell Lung Cancer
December 29th 2022According to Benjamin P. Levy, MD, clinicians can use the information currently available to best decide the treatment sequence of immunotherapy vs targeted agents in locally advanced non–small cell lung cancer.
Read More
Low Receipt of ACR-Recommended Follow-Care Discovered Among Patients With Lung Cancer
December 27th 2022According to a prospective study of lung cancer screening examinations conducted over a 5-year period, there is low adherence to guidelines recommending follow-up radiologic imaging or diagnostic procedures in patient with lung cancer.
Read More
Dr Shiller emphasizes the heterogeneity between the various EGFR exon 20 mutations seen in patients with NSCLC, and describes strategies for effectively communicating actionable information about a patient’s mutation status to the clinicians receiving the reports.
Watch
CHRYSALIS Data on Amivantamab and a Comparative Efficacy Analysis of Mobocertinib vs Amivantamab
Dr Neal discusses the design and outcomes of the CHRYSALIS study, investigating amivantamab for the treatment of EGFR exon 20-mutant advanced or metastatic lung cancer, and then briefly comments on a matched analysis of efficacy data on mobocertinib and amivantamab.
Watch
In the second installment of this series, Edward B. Garon, MD, MS, explains the rationale for using combination IO therapies alongside chemotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC), discusses key data from the POSEIDON trial presented at recent meetings, and elaborates on how these regimens may change his clinical practice.
Watch
Roundtable Discussion: Forde Reviews Chemoimmunotherapy as Treatment for Squamous NSCLC
December 19th 2022During a Targeted Oncology case-based roundtable event, Patrick Forde, MBBCh, discussed the use of the regimen consisting of nivolumab, ipilimumab, and 2 cycles of chemotherapy for non–small cell lung cancer.
Read More